Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-302 and S-1 Plus Paclitaxel +/- Cadonilimab in Claudin 18.2-positive Gastric Cancer
NCT07556640Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tpx-4589 and cadonilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Ruijin Hospital. Primary endpoint: 1-year survival rate at 24 months. Started Apr 2026; status: recruiting.
02
Drugs
tpx-4589cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07556640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556640.